Back to Resources
Market Highlights
- During Q3 2025, corporations within the European leukemia and lymphoma market touted new indications, efficacy, safety, dosing, and mechanisms of action for their respective brands. A new campaign also premiered.
- BeOne Medicines touted Brukinsa’s NICE recommendation and reimbursement for a fourth indication in the UK. The brand’s efficacy and safety were also promoted alongside two campaigns.
- The “Confidence” theme advertised Calquence’s approvals for mantle cell lymphoma and chronic lymphocytic leukemia.
- A press release touted Imbruvica’s European approval for mantle cell lymphoma. AstraZeneca also featured the “Time” campaign, which highlighted the brand’s new indication, efficacy, safety, dosing, and mechanism of action.
- Roche announced that Lunsumio’s subcutaneous formulation was recommended for approval by the CHMP.
- The “Every Path” campaign was introduced as AbbVie touted Venclyxto plus acalabrutinib’s approval for chronic lymphocytic leukemia, efficacy, and safety.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com